India's export revenue from biotechnology grew by 47 per cent to reach to 1.2 billion dollars in the financial year ended March 2007, a survey said.
India's biotech sector is expected to grow 25-30 per cent during the current fiscal over Rs 1,830 crore revenue generated during 2002-03, according to a joint survey by the Association of Biotechnology Led Enterprises and Biospectrum.
Association of Biotechnology Led Enterprises said customs duty at 12.5 per cent, excise/countervailing duty at 16.32 per cent, education cess at two per cent and additional duty on customs at four per cent result in 36.74 per cent increase in the price of cancer drugs, leading to cost to the patient going up.
Exports revenue of Indian biotech industry grew by 47 per cent during 2006-07 at Rs 4,937 crore (USD 1.2 billion), even as the total revenue, including the domestic figures, stood at Rs 8,541 crore (Rs 85.41 billion).
Sectors throw up a wishlist for the Finance Minister.
Green revolution and technology use should not be region-specific.
Eminent Indian-origin academician Srikant Datar has been named as Dean of Harvard Business School, succeeding Nitin Nohria and becoming the second consecutive dean hailing from India to lead the prestigious 112-year-old institution. Datar, an alumnus of University of Bombay and Indian Institute of Management, Ahmedabad, is the Arthur Lowes Dickinson Professor of Business Administration and the senior associate dean for University Affairs at Harvard Business School (HBS). He will assume charge as the school's next dean on January 1, president Larry Bacow said.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances